Evidence map›Paper›PMID 39000397›Full record

ArticleInternational journal of molecular sciences2024

The Prognostic and Therapeutic Potential of Fragile X Mental Retardation 1 (

Salem Baldi, Bushra Amer, Fawze Alnadari, Maged Al-Mogahed, Yaqin Gao, Yaser Gamallat

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Epitranscriptomics Regulation of CD70, CD80, and TIGIT in Cancer Immunity.International journal of molecular sciences · 2025
    Article
  2. Review
  3. Biomolecules · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Salem BaldiDepartment of Medical Laboratory Diagnostics, School of Medical Technology, Shaoyang University, Shaoyang 422000, China.ORCID 0000-0001-6711-1125
Bushra AmerDepartment of Family Medicine, Michigan State University, East Lansing, MI 49684, USA.
Fawze AlnadariResearch and Development Center of Jiangsu Tianmeijian Nature Bioengineering Co., Ltd., Nanjing 210046, China.ORCID 0000-0002-0630-1766
Maged Al-MogahedDepartment of Surgery, The First Bethune Hospital of Jilin University, Changchun 130012, China.ORCID 0009-0004-1356-5067
Yaqin GaoDepartment of Ultrasound Diagnosis, Zhongda Hospital Southeast University, Nanjing 210009, China.
Yaser GamallatDepartment of Oncology, Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1M4, Canada.ORCID 0000-0001-9980-2107

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate adenocarcinoma (PRAD) is the second most common tumor associated with death. The role and mechanisms of the fragile X mental retardation 1 (

Indexed as

AdenocarcinomaFragile X Messenger Ribonucleoprotein 1Gene Expression Regulation, NeoplasticProstatic NeoplasmsAgedBiomarkers, TumorHumansMaleMiddle AgedPhosphatidylinositol 3-KinasesPrognosisProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesBiomarkers, TumorFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1MTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasescorrelationFMR1gene expressionPI3K_AKT_mTORPRAD

Identifiers

PMID39000397
PMCPMC11242135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.